The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women.

Background: The objective of our study was to identify the correlations between the tests currently used in ovarian reserve assessment: anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH) and antral follicle count (AFC) and to distinguish the most reliable markers for ovarian reserve in order to select an adequate strategy for the initial stages of infertility treatment.

Materials And Methods: In this prospective study, 112 infertile women were assessed. Subjects were divided into three age groups: group I <35 years (n=39), group II 35-40 years (n=31), and group III 41-46 years (n=42).

[Intracytoplasmic sperm injection for treatment of male infertility].

The results of 84 consecutive couples who underwent 94 cycles of in-vitro fertilization (IVF) augmented with intracytoplasmic sperm injection (ICSI) were analyzed. Inclusion criteria were previous total failed fertilization or unsuitable sperm parameters for conventional IVF. The rate of diploid fertilization was 61,7%; the implantation rate per embryo was 12,0% and the ongoing pregnancy rate per transfer was 30,0%.

[The role of ultrasound scanning of endometrium in the superovulation stimulation program during in vitro fertilization and embryo transfer].

The intensive introduction of in vitro fertilization and embryo transfer into the clinical practice of sterility treatment has conditioned the necessity of developing reliable methods of control of the response of ovaries to the application of gonadotropic hormones for stimulating superovulation. There is not sufficient data about prognostic value of ultrasound scanning of structure of endometrium before or after the day of HCG administration in IVF cycles. Several authors have revealed differences in endometrial structure between the women with or without pregnancy.

[Results of application of high daily doses of recombinant follicle stimulating hormone in different age groups of women in IVF program].

A prospective, randomized, comparative study has been carried out to investigate the effectiveness of administration of recombinant FSH (rFSH, Gonal-F) in doses 150 and 225 IU in different age groups of women. 63 patients started a long gonadotrophin-releasing hormone agonist protocol (GnRHa, Diphereline, 0,1 mg): 31 received rFSH 150 IU/day and 32 - 225 IU/day. The objective was to assess the impact of these dosing regimens in down-regulated women.

[The use of gonadotropin-releasing hormone agonist (GnRH-a) dipherelin 3,75 mg for in vitro fertilization program].

For the purpose of optimizing the superovulation stimulation and improving clinical outcome, the gonadotropin-releasing hormone (GnRH-a) agonist were successfully used in the in vitro fertilization program. Under observation were 200 women of the reproductive age with the average length of sterility 7,6+/-4,1 years. The causes of sterility were as follows: tubo-peritoneal factor 84 (42%), endometriosis 54 (27%), PCOS 24 (19%), unknown infertility 38 (19%).